Gilead’s stock has fallen 21% since April 30, underscoring investor questions about remdesivir’s potential

admin 4 years ago No Comments

This post was originally published on this site

In the four months since Gilead Sciences Inc. first received emergency authorization for its experimental COVID-19 drug remdesivir, its stock has done the opposite of what you would expect — it has dropped 21%.

Prev Article Next Article

Coronavirus update: 1.45 million cases worldwide, 83,471 deaths; Wuhan lifts travel ban, while U.S. case tally nears 400,000

admin April 8, 2020

The Ratings Game: Zscaler closes above $100 for first time on coronavirus work-from-home wave

admin June 1, 2020

Carl Icahn lands two JetBlue board seats days after disclosing stake in airline

admin February 16, 2024

NewsWatch: Seeing America again through new eyes

admin November 26, 2019

NewsWatch: Dow books a 150-point loss after President Trump says he will hold Friday news conference on China

admin May 28, 2020

Ban billionaires? What progressive Democrats don’t understand about the economy

admin October 10, 2019

About The Author

admin

in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

By signing up above you will receive the Daily Buzz Offers newsletter and 3rd party advertisements. Expect up to 5 messages per week from us. You can unsubscribe at any time at the bottom of any of our emails.

Related Posts

About The Author

admin